Research programme: antibody-based cancer therapeutics - Menarini/Oxford BioTherapeuticsAlternative Names: MEN-1309; OX-002
Latest Information Update: 06 Oct 2014
At a glance
- Originator Menarini; Oxford BioTherapeutics
- Class Antibodies; Drug conjugates; Immunoconjugates; Maytansinoids
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Breast cancer; Cancer; Non-Hodgkin's lymphoma